<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39360646</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Influenza outbreak during the surge of SARS-CoV-2 omicron in a metropolitan area from southern Brazil: genomic surveillance.</ArticleTitle><Pagination><StartPage>e29944</StartPage><MedlinePgn>e29944</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29944</ELocationID><Abstract><AbstractText>Influenza circulation was significantly affected in 2020-21 by the COVID-19 pandemic. During this time, few influenza cases were recorded. However, in the summer of 2021-22, an increase in atypical influenza cases was observed, leading to the resurgence of influenza in the southernmost state of Brazil, Rio Grande do Sul (RS). The present study aimed to identify the circulation of FLUAV, FLUBV and SARS-CoV-2 and characterize the influenza genomes in respiratory samples using high-throughput sequencing technology (HTS). Respiratory samples (n = 694) from patients in RS were selected between July 2021 and August 2022. The samples were typed using reverse transcriptase real-time PCR (RT-qPCR) and showed 32% (223/694) of the samples to be positive for SARS-CoV-2, 7% for FLUAV (H3) (49/694). FLUBV was not detected. RT-qPCR data also resulted in FLUAV and SARS-CoV-2 co-infections in 1.7% (4/223) of samples tested. Whole genome sequencing of FLUAV produced 15 complete genomes of the H3N2 subtype, phylogenetically classified in the 3C.2a1b.2a.2a.3 subclade and revealing the dominance of viruses in the southern region of Brazil. Mutation analysis identified 72 amino acid substitutions in all genes, highlighting ongoing genetic evolution with potential implications for vaccine effectiveness, viral fitness, and pathogenicity. This study underscores limitations in current surveillance systems, advocating for comprehensive data inclusion to enhance understanding of influenza epidemiology in southern Brazil. These findings contribute valuable insights to inform more effective public health responses and underscore the critical need for continuous genomic surveillance.</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Abreu Góes Pereira</LastName><ForeName>Vyctoria Malayhka</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0002-4833-4400</Identifier><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gularte</LastName><ForeName>Juliana Schons</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demoliner</LastName><ForeName>Meriane</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7160-7649</Identifier><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Mariana Soares</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girardi</LastName><ForeName>Viviane</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippi</LastName><ForeName>Micheli</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frohlich</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink</LastName><ForeName>Pietra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Alana Witt</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Helena Lage</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, FZEA- USP, University of Sao Paulo, Pirassununga, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afrough</LastName><ForeName>Babak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Health Security Agency, New Variant Assessment Platform (NVAP), UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kritz-Wilson</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Security Agency, New Variant Assessment Platform (NVAP), UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spilki</LastName><ForeName>Fernando Rosado</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Departamento de Virologia, Laboratório de Microbiologia Molecular, Universidade Feevale, Novo Hamburgo, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul</Agency><Country /></Grant><Grant><Agency>UK Department of Health and Social Care</Agency><Country /></Grant><Grant><Agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior</Agency><Country /></Grant><Grant><Agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</Agency><Country /></Grant><Grant><Agency>Financiadora de Estudos e Projetos</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="Y">Genome, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="Y">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19 pandemic</Keyword><Keyword MajorTopicYN="N">FLUAV (H3N2) Darwin</Keyword><Keyword MajorTopicYN="N">Rio Grande do Sul</Keyword><Keyword MajorTopicYN="N">genomic surveillance</Keyword><Keyword MajorTopicYN="N">influenza</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39360646</ArticleId><ArticleId IdType="doi">10.1002/jmv.29944</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>WHO. World Health Organization. Influenza (seasonal). Who.int. Accessed March 13, 2024. https://www.who.int/health-topics/influenza-seasonal#tab=tab_1</Citation></Reference><Reference><Citation>CDC. Centers for Disease Control and Prevention. Influenza (Flu). Key Facts About Influenza (Flu). Available in https://www.cdc.gov/flu/about/keyfacts.htm Accessed March 25, 2023.</Citation></Reference><Reference><Citation>UYEKI TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. The Lancet. 2022;v. 400(n. 10353):693‐706.</Citation></Reference><Reference><Citation>Zamarin D, García‐Sastre A, Xiao X, Wang R, Palese P. Influenza virus PB1‐F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog. 2005;1(1):e4. doi:10.1371/journal.ppat.0010004</Citation></Reference><Reference><Citation>Gaucherand L, Porter BK, Levene RE, et al. The influenza A virus endoribonuclease PA‐X usurps host mRNA processing machinery to limit host gene expression. Cell Rep. 2019;27(3):776‐792.e7. doi:10.1016/j.celrep.2019.03.063</Citation></Reference><Reference><Citation>Allen JD, Ross TM. H3N2 influenza viruses in humans: viral mechanisms, evolution, and evaluation. Hum Vaccines Immunother. 2018;14:1840‐1847.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control. Seasonal Influenza Surveillance Overview, 2020. Stockholm: ECDC; 2020. Accessed May 15 2024 https://www.ecdc.europa.eu/sites/default/files/documents/AER-seasonal-influenza-2020-final.pdf</Citation></Reference><Reference><Citation>LEE SS, VIBOUD C, PETERSEN E. Understanding the rebound of influenza in the post COVID‐19 pandemic period holds important clues for epidemiology and control. Int J Infect Dis. 2022;v. 122:1002‐1004.</Citation></Reference><Reference><Citation>CHAN CP, Wong NS, Leung CC, Lee SS. Positive impact of measures against COVID‐19 on reducing influenza in the Northern hemisphere. J Travel Med. 2020;v. 27(n. 8):taaa087.</Citation></Reference><Reference><Citation>NOTT R, Fuller TL, Brasil P, Nielsen‐Saines K. Out‐of‐season influenza during a COVID‐19 void in the state of Rio de Janeiro, Brazil: temperature matters. Vaccines. 2022;10:821. doi:10.3390/vaccines10050821</Citation></Reference><Reference><Citation>Faico‐Filho KS, Barbosa GR, Bellei N. Peculiar H3N2 outbreak in São Paulo during summer and emergence of the omicron variant. J Infect. 2022;85(1):90‐122. doi:10.1016/j.jinf.2022.04.007</Citation></Reference><Reference><Citation>Brasil.a. Ministério da Saúde. Boletim Epidemiológico Especial 127. 2022. Accessed May 25, 2024 May. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/covid-19/2022/boletim-epidemiologico-no-127-boletim-coe-coronavirus/view</Citation></Reference><Reference><Citation>da Silva MS, Gularte JS, Filippi M, et al. Genomic and epidemiologic surveillance of SARS‐CoV‐2 in Southern Brazil and identification of a new Omicron‐L452R sublineage. Virus Res. 2022;321:198907. doi:10.1016/j.virusres.2022.198907</Citation></Reference><Reference><Citation>WHO. World Health Organization. Classification of Omicron (B.1.1.529): SARS‐CoV‐2 Variant of Concern. Available in https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern</Citation></Reference><Reference><Citation>Brasil.b. Ministério da Saúde. Painel Coronavírus. Available in https://covid.saude.gov.br/. 2020a Accessed March 24, 2024.</Citation></Reference><Reference><Citation>Rattanaburi S, Sawaswong V, Nimsamer P, et al. Genome characterization and mutation analysis of human influenza A virus in Thailand. Genomics Inform. 2022;20(2):e21. doi:10.5808/gi.21077</Citation></Reference><Reference><Citation>WHO. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2022 southern hemisphere influenza season September 2021 Dashboard. Accessed April 2023. https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-southern-hemisphere-influenza-season</Citation></Reference><Reference><Citation>WHO. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2023 southern hemisphere influenza season September 2022 Dashboard. Accessed May 2024. https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-southern-hemisphere-influenza-season</Citation></Reference><Reference><Citation>WHO. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season September 2023 Dashboard. Accessed May 2024 https://www.who.int/news/item/29-09-2023-recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season</Citation></Reference><Reference><Citation>Imai K, Tamura K, Tanigaki T, et al. Whole genome sequencing of influenza A and B viruses with the MinION sequencer in the clinical setting: a pilot study. Front Microbiol. 2018;9:2748. Published 2018 Nov 13. doi:10.3389/fmicb.2018.02748</Citation></Reference><Reference><Citation>Pérez‐Losada M, Arenas M, Galán JC, et al. High‐throughput sequencing (HTS) for the analysis of viral populations. Infect Genet Evol. 2020;80:104208. doi:10.1016/j.meegid.2020.104208</Citation></Reference><Reference><Citation>CDC – Centers for Disease Control and Prevention. CDC protocol of realtime RTPCR for swine influenza A (H1N1). v. 1, n. April 2009.</Citation></Reference><Reference><Citation>RÖNKKÖ E, Ikonen N, Kontio M, et al. Validation and diagnostic application of NS and HA gene‐specific real‐time reverse transcription‐PCR assays for detection of 2009 pandemic influenza A (H1N1) viruses in clinical specimens. J Clin Microbiol. 2011;49(5):2009‐2011.</Citation></Reference><Reference><Citation>TSE H, et al. Clinical and virological factors associated with viremia in pandemic influenza A/H1N1/2009 virus infection. PLoS One. 2011;6(9):e22534.</Citation></Reference><Reference><Citation>Selvaraju SB, Selvarangan R. Evaluation of three influenza A and B real‐time reverse transcription‐PCR assays and a new 2009 H1N1 assay for detection of influenza viruses. J Clin Microbiol. 2010.48, 11, 3870‐3875.</Citation></Reference><Reference><Citation>CORMAN VM, et al. Detection of 2019 novel coronavirus (2019‐nCoV) by real time RT‐PCR. Euro Surveill. 2020;25(3):1‐8.</Citation></Reference><Reference><Citation>Gregianini TS, Varella IRS, Fisch P, Martins LG, Veiga ABG. Dual and triple infections with influenza A and B viruses: a case‐control study in Southern Brazil. J Infect Dis. 2019;220(6):961‐968. doi:10.1093/infdis/jiz221</Citation></Reference><Reference><Citation>Gorini da Veiga AB, Kretzmann NA, Corrêa LT, et al. Viral load and epidemiological profile of patients infected by pandemic influenza a (H1N1) 2009 and seasonal influenza a virus in Southern Brazil. J Med Virol. 2012;84(3):371‐379. doi:10.1002/jmv.23198</Citation></Reference><Reference><Citation>Brasil.c. Ministério da Saúde. Boletim Epidemiológico Especial 52. 2020. Accessed 24 May 2024. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/covid-19/2020/boletim-epidemiologico-covid-19-no-52.pdf/view</Citation></Reference><Reference><Citation>Brasil.d. Ministério da Saúde. Boletim Epidemiológico Especial 92. 2021. Accessed 24 May 2024. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/covid-19/2021/boletim_epidemiologico_covid_92_10dez21.pdf/view</Citation></Reference><Reference><Citation>Fujita DM, Dos Santos Soares G, Sartori GP, Henrique da Silva Nali L. COVID‐19 and influenza coinfection: the rise of ômicron and H3N2 in Brazil–2022. Travel Med Infect Dis. 2022;46:102262. doi:10.1016/j.tmaid.2022.102262</Citation></Reference><Reference><Citation>Brasil.e. Ministério da Saúde. PORTARIA GM/MS N° 3.148, DE 6 DE FEVEREIRO DE 2024. Accessed June 11, 2024: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2024/prt3148_15_02_2024.html</Citation></Reference><Reference><Citation>Santos CAD, Bezerra GVB, Marinho ARRAA, et al. SARS‐CoV‐2/influenza A (H3N2) virus coinfection: epidemiological surveillance in northeast Brazil. Rev Soc Bras Med Trop. 2022;55:e0132. doi:10.1590/0037-8682-0132-2022</Citation></Reference><Reference><Citation>Dao TL, Hoang VT, Colson P, Million M, Gautret P. Co‐infection of SARS‐CoV‐2 and influenza viruses: a systematic review and meta‐analysis. J Clin Virol Plus. 2021;1(3):100036. doi:10.1016/j.jcvp.2021.100036</Citation></Reference><Reference><Citation>Lau LLH, Cowling BJ, Fang VJ, et al. Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis. 2010;201(10):1509‐1516. doi:10.1086/652241</Citation></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS‐CoV‐2, SARS‐CoV, and MERS‐CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta‐analysis. The Lancet Microbe. 2021;2(1):e13‐e22. doi:10.1016/S2666-5247(20)30172-5</Citation></Reference><Reference><Citation>O'Neill G, Aziz A, Kuba M, et al. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for reference and research on influenza during 2020‐2021. Commun Dis Intell. 2022;46. https://pubmed.ncbi.nlm.nih.gov/36154657/#:~:text=As%20part%20of%20its%20role,December%202021%20(2020%3A%20n%20%3D</Citation></Reference><Reference><Citation>Potter BI, Kondor R, Hadfield J, et al. Evolution and rapid spread of a reassortant A(H3N2) virus that predominated the 2017‐2018 influenza season. Virus Evol. 2019;5(2):vez046. doi:10.1093/ve/vez046</Citation></Reference><Reference><Citation>Korsun N, Angelova S, Trifonova I, et al. Predominance of influenza A(H3N2) viruses during the 2016/2017 season in Bulgaria. J Med Microbiol. 2018;67(2):228‐239. doi:10.1099/jmm.0.000668</Citation></Reference><Reference><Citation>Boonnak K, Mansanguan C, Schuerch D, et al. Molecular characterization of seasonal influenza A and B from hospitalized patients in Thailand in 2018‐2019. Viruses. 2021;13(6):977. doi:10.3390/v13060977</Citation></Reference><Reference><Citation>Nath Neerukonda S, Vassell R, Weiss CD. Neutralizing antibodies targeting the conserved stem region of influenza hemagglutinin. Vaccines. 2020;8(3):382. doi:10.3390/vaccines8030382</Citation></Reference><Reference><Citation>WHO. World Health Organization. Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs). Accessed February 2024: https://www.who.int/publications/m/item/summary-of-neuraminidase-(na)-amino-acid-substitutions-associated-with-reduced-inhibition-by-neuraminidase-inhibitors-(nais)</Citation></Reference><Reference><Citation>Chauhan RP, Gordon ML. An overview of influenza A virus genes, protein functions, and replication cycle highlighting important updates. Virus Genes. 2022;58(4):255‐269. doi:10.1007/s11262-022-01904-w</Citation></Reference><Reference><Citation>Guilligay D, Tarendeau F, Resa‐Infante P, et al. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol. 2008;15(5):500‐506. doi:10.1038/nsmb.1421</Citation></Reference><Reference><Citation>Sun T, Guo Y, Zhao L, et al. Evolution of the PB1 gene of human influenza A (H3N2) viruses circulating between 1968 and 2019. Transbound Emerg Dis. 2022;69(4):1824‐1836. doi:10.1111/tbed.14161</Citation></Reference><Reference><Citation>Elderfield RA, Watson SJ, Godlee A, et al. Accumulation of human‐adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom. J Virol. 2014;88(22):13269‐13283. doi:10.1128/JVI.01636-14</Citation></Reference><Reference><Citation>WHO. World Health Organization. Summary of polymerase acidic (PA) protein amino acid substitutions analysed for their effects on baloxavir susceptibility. Accessed February 2024: https://www.who.int/publications/m/item/summary-of-polymerase-acidic-(pa)-protein-amino-acid-substitutions-analysed-for-their-effects-on-baloxavir-susceptibility</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>